Try our Advanced Search for more refined results

Expert Analysis

Unpacking The Latest Trends In Biologics-Related IPRs

By Justin Rosinski, Michael Green, Richard Praseuth and John Josef Molenda (June 4, 2021, 4:51 PM EDT) -- In a previous Law360 guest article,[1] we analyzed statistical trends in the 98 biologics-related inter partes review petitions filed in the first four and a half years of the IPR procedure, namely Sept. 16, 2012, to April 12, 2017. As part of that analysis, we explored the underlying bases for those trends and how they related to concurrent developments in the biologics and biosimilars industry....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!